JGC
NBIX icon

J. Goldman & Co’s Neurocrine Biosciences NBIX Stock Holding History

J. Goldman & Co’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-53,303
Closed -$7.56M – 811
2025
Q4 		$7.56M Buy
53,303
+6,375
+14% +$924K 0.2% 144
2025
Q3 		$6.59M Sell
46,928
-37,307
-44% -$5.05M 0.17% 168
2025
Q2 		$10.6M Sell
84,235
-13,316
-14% -$1.53M 0.25% 128
2025
Q1 		$10.8M Buy
97,551
+51,825
+113% +$6.57M 0.27% 120
2024
Q4 		$6.24M Buy
+45,726
New +$5.66M 0.16% 180
2024
Q3 		– Sell
-35,721
Closed -$4.92M – 566
2024
Q2 		$4.92M Buy
35,721
+15,819
+79% +$2.17M 0.14% 175
2024
Q1 		$2.74M Buy
+19,902
New +$2.72M 0.09% 194
2023
Q4 		– Sell
-79,885
Closed -$9.2M – 429
2023
Q3 		$8.99M Sell
79,885
-5,489
-6% -$578K 0.31% 96
2023
Q2 		$8.05M Buy
85,374
+76,652
+879% +$7.49M 0.29% 97
2023
Q1 		$883K Buy
+8,722
New +$908K 0.04% 236
2022
Q4 		– Sell
-45,413
Closed -$4.82M – 453
2022
Q3 		$4.82M Buy
45,413
+37,831
+499% +$3.84M 0.23% 123
2022
Q2 		$739K Buy
+7,582
New +$700K 0.04% 264
2017
Q2 		– Sell
-46,700
Closed -$2.02M – 385
2017
Q1 		$2.02M Buy
+46,700
New +$2M 0.1% 206

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

J. Goldman & Co's NBIX Position: Q1 2026 in Review

J. Goldman & Co sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 53,303 shares — an estimated $7.56M sold.

J. Goldman & Co first reported a position in NBIX in Q1 2017 and held it in 13 quarters. The position peaked at $10.8M in Q1 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • J. Goldman & Co reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • J. Goldman & Co sold 53,303 Neurocrine Biosciences shares in Q1 2026, an estimated $7.56M.
  • J. Goldman & Co first reported a position in Neurocrine Biosciences in Q1 2017 and held it in 13 quarters.
  • J. Goldman & Co's Neurocrine Biosciences position peaked at $10.8M in Q1 2025.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.